Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Sep 04, 2019
The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies. Opdivo, leading drug of Bristol-Myers Squibb approv...
Read More...
Aug 24, 2018
Hepato Cellular Carcinoma (HCC) Not all deadly battles are lost. Some are won too.It is without the slightest doubt that the ones won are the typical examples of smart management, involving implementation of prudent steps, guided by the knowledge of every nook and corner. Undoubtedly, these examples not only serve ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper